Loading
Obesity and Health Practices / Nutrition, Genetics, and Disease · Journal article
Nutrients · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a retrospective, uncontrolled descriptive analysis of a real-world obesity care pathway integrating digital phenotyping and exchange-based nutrition. Mean weight loss of 4.3 kg (−3.4% median) was observed, but the authors explicitly state causality cannot be attributed to the pathway, Dietcamb®, or medication effect in this selected, uncontrolled cohort. Prospective controlled studies are needed to establish independent effectiveness.
Retrospective observational cohort study, descriptive and operational. Routine-care patients in the OBEDIGITHUM pathway with plausible baseline weight and observable 6-month follow-up window. Baseline: mean age 53.7 ± 14.0 years, 70.5% women, mean BMI 35.9 ± 6.3 kg/m².. Intervention: NUTRI-OBEDIGITHUM pathway integrating multidimensional digital phenotyping, clinician-supervised exchange-based nutritional prescription via Dietcamb® software, patient-oriented materials, and structured education.. n = 929.
Mean weight change −4.3 kg (95% CI −4.7 to −3.9 kg) from baseline 98.5 kg to follow-up 94.2 kg over 6 months Median total body-weight loss 3.4%; 39.6% achieved ≥5% loss, 17.8% achieved ≥10% loss, 6.4% achieved ≥15% loss 6-month follow-up weight available for 929 of 3215 patients (28.9%); 2286 (71.1%) lacked eligible outcome measurement
No control or comparison arm; causality cannot be established for the pathway, Dietcamb®, or pharmacotherapy contribution GLP-1 receptor-agonist use detected by free-text only; medication timing, dose, adherence, and persistence data absent, limiting ability to adjust for pharmacotherapy confounding
Clinicians should recognize this as an operational description of a structured, digital obesity care pathway that incorporates exchange-based nutrition and shows modest weight loss in a real-world setting. However, the uncontrolled design, 71% loss to outcome ascertainment, and undocumented confounders (particularly GLP-1 use) prevent attribution of the observed weight change to the pathway itself; prospective controlled trials are essential before implementation decisions.
Descriptive real-world cohort analysis without control group, prospective design, or mechanism of action attribution; weight loss observed but causality to the pathway cannot be established from this uncontrolled, selected cohort.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as an operational description of a structured, digital obesity care pathway that incorporates exchange-based nutrition and shows modest weight loss in a real-world setting. However, the uncontrolled design, 71% loss to outcome ascertainment, and undocumented confounders (particularly GLP-1 use) prevent attribution of the observed weight change to the pathway itself; prospective controlled trials are essential before implementation decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Obesity care requires nutritional prescriptions that are individualized, nutritionally coherent, understandable, and feasible within high-volume clinical services. We describe the NUTRI-OBEDIGITHUM pathway, which integrates multidimensional digital phenotyping, clinician-supervised exchange-based nutritional prescription, patient-oriented materials, and structured education, and we report preliminary descriptive outcomes from a retrospective real-world cohort. Methods: This descriptive methodological and operational study included a retrospective observational analysis of anonymized routine-care data. NUTRI-OBEDIGITHUM integrates OBEDIGITHUM, a digitally enabled obesity-care pathway, with Dietcamb®, a software-supported method that translates individualized energy and macronutrient targets into food exchanges, meal distributions, household measures, food lists, and example menus. The source database comprised 3928 unique patients. Among patients with a plausible baseline weight and an observable 6-month window, the eligible outcome was the measurement closest to day 183 within ±60 days, after prespecified plausibility checks. Baseline characteristics were compared descriptively according to outcome availability. Baseline medication exposure was assessed using free-text mentions only. Results: By the data cutoff, the 6-month window had opened for 3215 patients; 929 (28.9%) had an eligible 6-month weight and 2286 (71.1%) did not. In the analyzed cohort, mean age was 53.7 ± 14.0 years, 70.5% were women, and mean body mass index was 35.9 ± 6.3 kg/m2. Mean weight changed from 98.5 ± 20.7 kg at baseline to 94.2 ± 20.3 kg at follow-up, corresponding to a descriptive paired change of −4.3 kg (95% CI −4.7 to −3.9); median total body-weight loss was 3.4%. Losses of at least 5%, 10%, and 15% were observed in 39.6%, 17.8%, and 6.4% of patients, respectively. A baseline GLP-1 receptor-agonist mention was present in 151/929 patients (16.3%); medication timing, dose, duration, dispensing, persistence, and adherence were unavailable. Conclusions: NUTRI-OBEDIGITHUM provides an operational framework for converting multidimensional obesity phenotyping into a structured, flexible, clinician-supervised, and patient-oriented nutritional prescription. The observed weight trajectories are descriptive complete-case findings from a selected, uncontrolled cohort and cannot establish the independent effectiveness of the pathway, Dietcamb®, or pharmacotherapy. Prospective studies should evaluate reach, adoption, fidelity, usability, adherence, nutritional adequacy, safety, NUTRI-specific workload and cost, and metabolic outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.